Enveric Biosciences, Inc. (ENVB)

Enveric Biosciences' stock price has declined significantly over the past six months. Key events include a 1-for-12 reverse stock split on October 28, 2025, capital raises totaling $12.2 million in fiscal year 2025, and approximately $2.95 million in January and February 2026. The company reported a net loss of $4.0 million for the quarter ended December 31, 2025. In March 2026, Enveric Biosciences announced it received a U.S. patent covering its EVM301 drug series, and in February 2026, Gilgamesh Pharmaceuticals withdrew a Post-Grant Review petition against an Enveric patent.

Enveric Biosciences does not experience traditional demand seasonality due to its focus on drug discovery and development. Revenue generation is tied to milestones in drug development, potential licensing agreements, and eventual commercialization rather than consumer purchasing cycles. Demand for its pipeline products will be driven by medical need and market adoption.

Enveric Biosciences, Inc. is a biotechnology company focused on developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. Their lead product candidate, EB-003, is being advanced towards clinical trials for mental health disorders. Other programs include EB-002, EVM-301 Series, EV104 CBD + Celecoxib conjugate, a cannabinoid-infused topical solution, and a cannabinoid-COX-2 inhibitor conjugation intervention. The company utilizes its Psybrary™ platform to build its intellectual property portfolio.

Enveric Biosciences relocated its headquarters to Cambridge, Massachusetts, in September 2025 to leverage the biotech hub. They also maintain offices in Calgary, Alberta, Canada.

Enveric Biosciences' brand reputation has been influenced by its scientific advancements and intellectual property developments. The withdrawal of a patent challenge by Gilgamesh Pharmaceuticals and positive preclinical results for EB-003 have contributed to its reputation.

As of March 2026, institutional investors own 13.82% of Enveric Biosciences' stock. Major institutional owners include AdvisorShares Investments LLC, UBS Group AG, and Citigroup Inc. Individual insiders own 14.54% of the stock, with CEO Joseph Edward Tucker being the largest individual shareholder. Retail investors hold 84.18%.